
News|Slideshows|August 11, 2021
8 Questions on Diabetes Drugs for Cardioprotection
Author(s)Leo Robert
Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.
Advertisement
Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.
Take this quick quiz to test your knowledge of key findings.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Needle Anxiety and Injection Site Pain: Evidence-Based Strategies for Patient Counseling on Injectable PrEP
2
Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD
3
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
4
Noninvasive CRC Screening Needs More Primary Care Advocates: Thoughts from Mark Fendrick, MD
5

















































































































































































































































































